DNLI
Denali Therapeutics Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -10.3% · nuevas posiciones netas -5.3% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | +7 | 103.65M | $2.65B | +11 | −5 |
| Q1 2026 | 93 | +4 | 96.77M | $1.85B | +11 | −8 |
| Q4 2025 | 89 | 0 | 110.68M | $1.83B | +1 | n/a |
| Q3 2025 | 19 | 0 | 67.26M | $976.61M | n/a | −1 |
| Q2 2025 | 17 | +1 | 74.76M | $1.05B | +2 | −1 |
| Q1 2025 | 13 | +1 | 44.98M | $611.55M | +2 | −1 |
| Q4 2024 | 12 | -1 | 38.31M | $780.78M | n/a | −1 |
| Q3 2024 | 12 | 0 | 34.10M | $993.27M | +1 | −1 |
| Q2 2024 | 12 | n/a | 35.56M | $825.78M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 12.29M | +2.0% | $178.45M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (pasivo) | 11.99M | +1.5% | $174.14M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | Baillie Gifford ✦ | 11.59M | -3.0% | $168.31M | 0.1% | ▼ Trim | 6 | SEC ↗ ×4 |
| 4 | Fidelity (FMR) ✦ | 6.34M | -15.9% | $92.06M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (pasivo) | 5.46M | +20.9% | $79.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 4.57M | -30.6% | $66.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Geode Capital Management ✦ (pasivo) | 3.47M | +9.3% | $50.34M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Point72 Asset Management ✦ | 2.52M | +13.8% | $36.58M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Goldman Sachs Group ✦ | 2.16M | n/a | $31.42M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Morgan Stanley ✦ | 1.69M | n/a | $24.53M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 11 | Fisher Asset Management ✦ | 1.63M | +7.6% | $23.69M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Millennium Management ✦ | 1.31M | +45.2% | $18.98M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Marshall Wace ✦ | 787.03K | -44.0% | $11.43M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 688.22K | -44.9% | $9.99M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | JPMorgan Chase ✦ | 350.04K | n/a | $5.08M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 16 | Two Sigma Investments ✦ | 266.29K | +1279.8% | $3.87M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Renaissance Technologies ✦ | 59.80K | -69.4% | $868,296 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 59.23K | -99.0% | $860,078 | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 19 | AQR Capital Management ✦ | 24.14K | +13.8% | $350,498 | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Sin nuevos compradores rastreados este trimestre. |
Posición cerrada
| Norges Bank | $55.22M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 265 tenedores, 147.10M acciones, $2.60B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 1.65K acc. · $36,868
Director · 10.82K acc. · $247,328
Director · 615 acc. · $14,600
Officer · 2.77K acc. · $64,882
Officer · 2.86K acc. · $71,625
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología